|
Video: What is a Stock Split?
|
|
Kintara Therapeutics is a clinical stage biopharmaceutical company. Co.'s two primary candidates are: VAL-083, a validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer. PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. According to our KTRA split history records, Kintara Therapeutics has had 1 split. | |
|
Kintara Therapeutics (KTRA) has 1 split in our KTRA split history database. The split for KTRA took place on November 14, 2022. This was a 1 for 50 reverse split, meaning for each 50 shares of KTRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split.
When a company such as Kintara Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the KTRA split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kintara Therapeutics shares, starting with a $10,000 purchase of KTRA, presented on a split-history-adjusted basis factoring in the complete KTRA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$58.50 |
|
End price/share: |
$0.10 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.82% |
|
Average Annual Total Return: |
-46.92% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$17.79 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
11/14/2022 | 1 for 50 |
|
|